Tools for Enabling Process Analytical Technology Applications in Biotechnology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tools for Enabling Process Analytical Technology Applications in Biotechnology
The success of process analytical technology (PAT), a recent initiative by FDA, depends to a large extent on efficient control of manufacturing processes to achieve predefined quality of the final product. In this paper, the authors review the various analytical methods that can enable use of PAT.


Pharmaceutical Technology
pp. s16-s22, s28-s31

27. K. Hipkins, Pharm. Tech. Eur. 2, 157–163 (2007).

28. C. Justice et al., Biotechnol. Adv. 29, 391–401 (2011).

29. A. Sharma, and S.G. Schulman, Wiley InterScience 2, 172–176 (1999).

30. S. Marose, C. Lindemann, and T. Scheper, Biotech. Progress 14, 63–74, (1998).

31. P. Ana Teixeira et al., Wiley InterScience 102, 1108–1116 (2008).

32. P. Ana Teixeira, M. Tiago Duarte, M.J.T. Carrondo, and M. Paula Alves, Biotechnol.Bioeng. 102, 1852–1861 (2011).

33. M. Reinecke and T. Scheper, J. Biotechnol. 17, 145–53 (1997).

34. A.S. Rathore, L. Parr, S. Dermawan, K. Lawson, and Y. Lu, Biotechnol. Prog. 26, 448–57 (2010).

35. A.S. Rathore, R. Wood, A. Sharma, and S. Dermawan, Biotechnol. Bioeng. 101, 1366–1374 (2008).

36. A.S. Rathore, A. Sharma, and D. Chilin, BioPharm Int. 19, 48–57 (2006).

37. M. Tina Larson et al., Biotech. and Bioengin. 77, 553–563 (2002).

38. R.L. Fahrner et al., J. Chromatogr. A. 827, 37–43 (1998).

39. J. Barackman, I.Prado, C. Karunatilake, and K. Furuya, J. Chromatogr. A. 16, 57–64 (2004).

40. C. Bittner, G. Wehnert, and T. Scheper, Biotechnol. Bioeng. 60, 24–35 (1998).

41. V. Camisard et al., Biotechnol. Bioeng. 78, 73–80 (2002).

42. J.S. Guez et al., J. Biotechnol. 111, 335–343 (2004).

43. G. Rudolph et al., Biotechnol. Bioeng. 99, 136–145 (2008).

44. N. Wei et al., Biotechnol. Lett. 29, 373–378 (2007).

45. A. Prediger et al., Chem. Engin. & Tech. 34, 837–840 (2011).

46. C. Buschmüller et al., Eur. J. Pharm. Biopharm. 69, 380–387 (2008).

47. http://www.nature.com/naturephotonics/.

48. M.P. Wagh, Y.H. Sonawane, and O.U. Joshi., Indian J. Pharm. Sci. 71, 235–241 (2009).

49. H. Wu, E.J. Heilweil, A.S, Hussain, and M.A. Khan, J. Pharm. Sci. 97, 970–984 (2008).

50. T. Schmid, Anal. Bioanal. Chem. 384, 1071–1086 (2006).

51. V. Deepak Bageshwar, S. Avinash Pawar, V. Vineeta Khanvilkar, and J. Vilasrao Kadam, Eurasian J. Anal. Chem. 5, 187–203 (2010).

52. T. Schmid et al., Environ. Sci. Technol. 36, 4135–4141 (2002).

53. http://pharma.metrohm.com/pdfdownload/Prosp_Pharma_Analytik_e_web.pdf.

54. W. Chew and P. Sharratt, Anal. Methods 2, 1412–1438 (2010).

55. P. Werle, R. Mücke, and F. Slemr, App. Phys. B: Lasers and Optics 57, 131–139 (1993).

56. S. Armenta, S. Garrigues, M. Gauradia, and P. Rondeau, Anal. Chem. Acta. 545, 99–106 (2005).

57. A.S. Rathore, R. Bhambure, and V. Ghare, Bioanal. Chem. 398, 137–154 (2010).

*This article was previously published in the January 2012 issue of LCGC North America.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here